Supplemental parenteral nutrition enriched with omega-3 polyunsaturated fatty acids in intensive care patients – a randomized, controlled, double-blind clinical trial

2021 ◽  
Vol 46 ◽  
pp. S565
Author(s):  
P. Singer ◽  
R. Mesalati-Stahzi ◽  
I. Bendavid ◽  
M. Theilla ◽  
A. Ariel ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Fatty Acids ◽  
Intensive Care ◽  
Parenteral Nutrition ◽  
Polyunsaturated Fatty Acids ◽  
Omega 3 ◽  
Double Blind ◽  
Intensive Care Patients ◽  
Randomized Controlled ◽  
Double Blind Clinical Trial

scholarly journals Home parenteral nutrition with an omega-3-fatty-acid-enriched MCT/LCT lipid emulsion in patients with chronic intestinal failure (the HOME study): study protocol for a randomized, controlled, multicenter, international clinical trial

Trials ◽  
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Stanislaw Klek ◽  
Cécile Chambrier ◽  
Sheldon C. Cooper ◽  
Simon Gabe ◽  
Marek Kunecki ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Fatty Acids ◽  
Liver Function ◽  
Parenteral Nutrition ◽  
Intestinal Failure ◽  
Home Parenteral Nutrition ◽  
Omega 3 ◽  
Home Study ◽  
Randomized Controlled ◽  
International Clinical Trial

Abstract Background Home parenteral nutrition (HPN) is a life-preserving therapy for patients with chronic intestinal failure (CIF) indicated for patients who cannot achieve their nutritional requirements by enteral intake. Intravenously administered lipid emulsions (ILEs) are an essential component of HPN, providing energy and essential fatty acids, but can become a risk factor for intestinal-failure-associated liver disease (IFALD). In HPN patients, major effort is taken in the prevention of IFALD. Novel ILEs containing a proportion of omega-3 polyunsaturated fatty acids (n-3 PUFA) could be of benefit, but the data on the use of n-3 PUFA in HPN patients are still limited. Methods/design The HOME study is a prospective, randomized, controlled, double-blind, multicenter, international clinical trial conducted in European hospitals that treat HPN patients. A total of 160 patients (80 per group) will be randomly assigned to receive the n-3 PUFA-enriched medium/long-chain triglyceride (MCT/LCT) ILE (Lipidem/Lipoplus® 200 mg/ml, B. Braun Melsungen AG) or the MCT/LCT ILE (Lipofundin® MCT/LCT/Medialipide® 20%, B. Braun Melsungen AG) for a projected period of 8 weeks. The primary endpoint is the combined change of liver function parameters (total bilirubin, aspartate transaminase and alanine transaminase) from baseline to final visit. Secondary objectives are the further evaluation of the safety and tolerability as well as the efficacy of the ILEs. Discussion Currently, there are only very few randomized controlled trials (RCTs) investigating the use of ILEs in HPN, and there are very few data at all on the use of n-3 PUFAs. The working hypothesis is that n-3 PUFA-enriched ILE is safe and well-tolerated especially with regard to liver function in patients requiring HPN. The expected outcome is to provide reliable data to support this thesis thanks to a considerable number of CIF patients, consequently to broaden the present evidence on the use of ILEs in HPN. Trial registration ClinicalTrials.gov, ID: NCT03282955. Registered on 14 September 2017.

scholarly journals Home parenteral nutrition with an omega-3 fatty acid enriched MCT/LCT lipid emulsion in patients with chronic intestinal failure (the HOME study): Study protocol for a randomized, controlled, multicenter, international clinical trial

2019 ◽  
Author(s):  
Stanislaw Klek ◽  
Cecile Chambrier ◽  
Sheldon C Cooper ◽  
Simon Gabe ◽  
Marek Kunecki ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Fatty Acids ◽  
Liver Function ◽  
Parenteral Nutrition ◽  
Intestinal Failure ◽  
Home Parenteral Nutrition ◽  
Omega 3 ◽  
Home Study ◽  
Randomized Controlled ◽  
International Clinical Trial

Abstract Background Home parenteral nutrition (HPN) is a life-preserving therapy for patients with chronic intestinal failure (CIF) indicated for patients who cannot achieve their nutritional requirements by enteral intake. Intravenous lipid emulsions (ILEs) are an essential component of HPN providing energy and essential fatty acids, but can become a risk factor for intestinal failure-associated liver disease (IFALD). In HPN patients, major effort is taken in the prevention of IFALD. Novel ILEs containing a proportion of omega-3 polyunsaturated fatty acids (n-3 PUFA) could be of benefit, but the data on the use of n-3 PUFA in HPN patients are still limited.Methods The HOME study is a prospective, randomized, controlled, double-blind, multicenter, international clinical trial conducted in European hospitals that treat HPN patients. A total of 160 patients (80 per group) will be randomly assigned to receive the n-3 PUFA enriched medium/long-chain triglyceride (MCT/LCT) ILE (Lipidem / Lipoplus ® 200 mg/ml, B. Braun Melsungen AG) or the MCT/LCT ILE (Lipofundin ® MCT/LCT / Medialipide ® 20%, B. Braun Melsungen AG) for a projected period of eight weeks. The primary endpoint is the combined change of liver function parameters (total bilirubin, aspartate transaminase and alanine transaminase) from baseline to final visit. Secondary objectives are the further evaluation of safety and tolerability as well as the efficacy of the ILEs.Discussion Currently, there are only very few randomized controlled trials (RCTs) investigating the use of ILEs in HPN, and there are very few data at all on the use of n-3 PUFAs. The aim of the HOME study is to demonstrate that the n-3 PUFA enriched ILE is safe and well tolerated especially with regard to liver function in patients requiring HPN. The study will provide data from a considerable number of CIF patients and thus contribute to broaden the present evidence on the use of ILEs in HPN.Trial registrationClinicalTrials.gov, NCT03282955, registered on September 14, 2017

A double- blind, randomized, and placebo-controlled clinical trial with omega-3 polyunsaturated fatty acids (OPFA ɷ-3) for the prevention of migraine in chronic migraine patients using amitriptyline

2017 ◽  
Vol 21 (3) ◽  
pp. 219-223 ◽  
Author(s):  
Adriana de Almeida Soares ◽  
Polyanna Mendes Camarço Louçana ◽  
Ema Pereira Nasi ◽  
Kamila Maria de Holanda Sousa ◽  
Odara Maria de Sousa Sá ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Fatty Acids ◽  
Polyunsaturated Fatty Acids ◽  
Chronic Migraine ◽  
Controlled Clinical Trial ◽  
Omega 3 ◽  
Double Blind

scholarly journals Home parenteral nutrition with an omega-3 fatty acid enriched MCT/LCT lipid emulsion in patients with chronic intestinal failure (the HOME study): Study protocol for a randomized, controlled, multicenter, international clinical trial

2019 ◽  
Author(s):  
Stanislaw Klek ◽  
Cecile Chambrier ◽  
Sheldon C Cooper ◽  
Simon Gabe ◽  
Marek Kunecki ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Fatty Acids ◽  
Liver Function ◽  
Parenteral Nutrition ◽  
Intestinal Failure ◽  
Home Parenteral Nutrition ◽  
Omega 3 ◽  
Home Study ◽  
Randomized Controlled ◽  
International Clinical Trial

Abstract Background Home parenteral nutrition (HPN) is a life-preserving therapy for patients with chronic intestinal failure (CIF) indicated for patients who cannot achieve their nutritional requirements by enteral intake. Intravenous lipid emulsions (ILEs) are an essential component of HPN providing energy and essential fatty acids, but can become a risk factor for intestinal failure-associated liver disease (IFALD). In HPN patients, major effort is taken in the prevention of IFALD. Novel ILEs containing a proportion of omega-3 polyunsaturated fatty acids (n-3 PUFA) could be of benefit, but the data on the use of n-3 PUFA in HPN patients are still limited.Methods The HOME study is a prospective, randomized, controlled, double-blind, multicenter, international clinical trial conducted in European hospitals that treat HPN patients. A total of 160 patients (80 per group) will be randomly assigned to receive the n-3 PUFA enriched medium/long-chain triglyceride (MCT/LCT) ILE (Lipidem / Lipoplus ® 200 mg/ml, B. Braun Melsungen AG) or the MCT/LCT ILE (Lipofundin ® MCT/LCT / Medialipide ® 20%, B. Braun Melsungen AG) for a projected period of eight weeks. The primary endpoint is the combined change of liver function parameters (total bilirubin, aspartate transaminase and alanine transaminase) from baseline to final visit. Secondary objectives are the further evaluation of safety and tolerability as well as the efficacy of the ILEs.Discussion Currently, there are only very few randomized controlled trials (RCTs) investigating the use of ILEs in HPN, and there are very few data at all on the use of n-3 PUFAs. The aim of the HOME study is to demonstrate that the n-3 PUFA enriched ILE is safe and well tolerated especially with regard to liver function in patients requiring HPN. The study will provide data from a considerable number of CIF patients and thus contribute to broaden the present evidence on the use of ILEs in HPN.

Sign in / Sign up

Export Citation Format

Share Document